Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination
IntroductionIn addition to its direct cytotoxic effects, ablative therapies as electrochemotherapy (ECT) can elicit indirect antitumor effects by triggering immune system responses. Here, we comprehensively analyzed this dual effectiveness of intratumoral ECT with chemotherapeutic drugs bleomycin (B...
Saved in:
Main Authors: | Katja Uršič Valentinuzzi, Urška Kamenšek, Simona Kranjc Brezar, Chloe Heranney, Tilen Komel, Simon Buček, Maja Čemažar, Gregor Serša |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1470432/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST) of low-flow vascular malformations
by: Muir Tobian, et al.
Published: (2024-11-01) -
CD146 promotes resistance of NSCLC brain metastases to pemetrexed via the NF-κB signaling pathway
by: Hao Qu, et al.
Published: (2025-01-01) -
Evaluation of the basophil activation in immediate type
hypersensitivity reactions to chemotherapeutic agents
by: Gözde Köycü Buhari, et al.
Published: (2024-02-01) -
REV7: a small but mighty regulator of genome maintenance and cancer development
by: Lara R. Maggs, et al.
Published: (2025-01-01) -
Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial
by: Jiamin Yu, et al.
Published: (2025-02-01)